# Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

> **NCT00114959** · PHASE2 · TERMINATED · sponsor: **ChemGenex Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic
- Myeloid Leukemia, Chronic, Accelerated-Phase
- Blast Phase
- Myeloid Leukemia, Chronic, Chronic-Phase

## Interventions

- **DRUG:** Homoharringtonine
- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT00114959
- **Lead sponsor:** ChemGenex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** 2008-06
- **Final completion:** 2009-03
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2015-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00114959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00114959, "Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00114959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*